Clinical Trial Detail

NCT ID NCT02818023
Title Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors University of Pittsburgh
Indications

mucosal melanoma

skin melanoma

melanoma

Therapies

Pembrolizumab + Vemurafenib

Age Groups: adult senior

Additional content available in CKB BOOST